Tempus AI, Inc.: insider trades · United States · SEC (Form 4)

About Tempus AI, Inc.

Tempus AI, Inc. is a U.S.-based healthcare technology company listed on the NASDAQ in the United States, operating at the intersection of artificial intelligence, genomics, and precision medicine. Founded in 2015 by Eric Lefkofsky in Chicago, the company was built around the idea that large-scale clinical and molecular data can materially improve treatment decisions, initially in oncology and increasingly across broader disease areas. Tempus is headquartered in Chicago, Illinois, and its commercial footprint is primarily U.S.-focused, serving hospitals, cancer centers, laboratories, researchers, and biopharma partners. Tempus’ business model is built on complementary revenue streams. Its diagnostics segment offers molecular and genomic testing designed to better characterize tumors and other complex conditions. In parallel, the company commercializes data, analytics, and AI-powered tools that help users leverage proprietary clinical and molecular datasets for research, biomarker discovery, clinical trial matching, and decision support. This diagnostics-plus-data/software structure is a key differentiator versus traditional lab-testing companies and versus health-software vendors that lack Tempus’ owned data assets. From a competitive standpoint, Tempus aims to become a leading precision-medicine platform. Its investment case rests on the scale and quality of its data, the integration between testing and software, and its ability to partner with pharmaceutical companies, academic institutions, and health systems. The company has also been emphasizing new AI-enabled products and strategic partnerships to strengthen its position in patient stratification, screening, and care optimization. Recent milestones underscore the company’s momentum. On May 5, 2026, Tempus reported first-quarter 2026 revenue of $348.1 million, up 36.1% year over year, and it highlighted multiple collaborations, including initiatives with Bristol Myers Squibb and USC. In early May 2026, Tempus also announced a $400 million convertible senior notes offering intended to optimize its capital structure and reduce interest expense. In addition, the company was named by TIME as one of the 10 Most Influential Health and Life Science Companies of 2026. For investors, Tempus remains a high-growth healthcare technology name with meaningful upside tied to data monetization and product adoption, but also with the usual execution, reimbursement, regulatory, and commercialization risks inherent in precision medicine.